SAN FRANCISCO, August 06, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ...

All three trials in the Company’s registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated.

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

We break down everything you need to know about the run/walk method and how it helps runners go faster and run farther.

Consider three seemingly unrelated developments. “You can’t hire Indians, set up factories in China and park profits in Ireland,” Trump said to US big-tech in mid-July, following this by ...

Staging TV programs and commercials how to plan and execute sets, props, and production facilities Smithsonian Libraries and Archives Object Details author Wade, Robert J 1907- Notes NMAH copy ...